A new trade probe is reigniting a long-running clash over who should pay for medical innovation. Washington argues Germans benefit from lower prices while US patients shoulder a disproportionate share of the costs.
About the Author
A new trade probe is reigniting a long-running clash over who should pay for medical innovation. Washington argues Germans benefit from lower prices while US patients shoulder a disproportionate share of the costs.